A meeting of the National Drug Scheduling Advisory Committee (NDSAC) was held on September 20, 2026, with the following interim recommendation made:

• Epinephrine nasal spray, when indicated for emergency treatment of anaphylactic reactions, be granted Schedule II status.

Any objections to this interim recommendation must be received by the NAPRA office by 4 p.m. Eastern time on October 28, 2026. Questions or comments should be directed to the NDSAC Secretariat via email at ndsac@napra.ca.